TRACON Pharmaceuticals Inc. (TCON)

Name: TRACON Pharmaceuticals Inc. (TCON) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: TRACON Pharmaceuticals Inc. (TCON)

Stock Card

$0.03

$-0.01 (-25.98%)

As on 16-Jul-2025 16:00EDT

Market cap

$0 Mln

Revenue (TTM)

$3 Mln

P/E Ratio

P/B Ratio

11.8

Div. Yield

0 %

TRACON Pharmaceuticals (TCON) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 0.03 High: 0.04

52 Week Range

Low: -- High: --

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-12.8 %
ROCE

-- %
Industry P/E

37.31
EV/EBITDA

-0.8
Debt to Equity

0
Book Value

$--
EPS

$3.8
Face value

--
Shares outstanding

3,407,610

10 Years Aggregate

CFO

$-174.41 Mln

EBITDA

$-206.67 Mln

Net Profit

$-213.90 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
TRACON Pharmaceuticals (TCON)	--	--	--	-95.9	-73.8	-56.1	-56.5
BSE Sensex^*	-8.8	0.6	1.8	-4.4	6.0	6.6	10.8
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 16-Jul-2025 | *As on 28-Aug-2026 | #As on 26-Oct-2023

Company	2023	2022	2021	2020	2019	2018	2017
TRACON Pharmaceuticals (TCON)	-88.3	-46.2	-76.3	400.0	-62.9	-81.0	-31.6
S&P Small-Cap 600	13.9	-17.4	25.3	9.6	20.9	-9.7	11.7
BSE Sensex	18.7	4.4	22.0	15.8	14.4	5.9	27.9

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Shareholding Pattern

View Details

About TRACON Pharmaceuticals (TCON)

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain... antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. In addition, it is developing bispecific antibodies, which are in preclinical stage. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309 and bispecific antibodies; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California. Read more

Chairman, CEO & President

Dr. Charles P. Theuer M.D., Ph.D.
Chairman, CEO & President

Dr. Charles P. Theuer M.D., Ph.D.
Headquarters

San Diego, CA
Website

https://www.traconpharma.com

FAQs for TRACON Pharmaceuticals (TCON)

What is the current share price of TRACON Pharmaceuticals Inc (TCON) Today?

The share price of TRACON Pharmaceuticals Inc (TCON) is $0.03 (NASDAQ) as of 16-Jul-2025 16:00 EDT. TRACON Pharmaceuticals Inc (TCON) has given a return of -73.8% in the last 3 years.

What is the current PB & PE ratio of TRACON Pharmaceuticals Inc (TCON)?

The P/E ratio of TRACON Pharmaceuticals Inc (TCON) is 0.01 times as on 16-Jul-2025, a 100 discount to its peers’ median range of 37.31 times.
The P/B ratio of TRACON Pharmaceuticals Inc (TCON) is 11.83 times as on 16-Jul-2025, a 53 premium to its peers’ median range of 7.75 times.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2023	-0.10	-0.43
2022	-0.06	-0.23
2021	-0.09	0.23
2020	-0.47	0.32
2019	-0.02	0.14

What is the 52 Week High and Low of TRACON Pharmaceuticals Inc (TCON)?

The 52-week high and low of TRACON Pharmaceuticals Inc (TCON) are Rs -- and Rs -- as of 30-Aug-2026.

What is the market cap of TRACON Pharmaceuticals Inc (TCON)?

TRACON Pharmaceuticals Inc (TCON) has a market capitalisation of $ 0 Mln as on 16-Jul-2025. As per SEBI classification, it is a Small Cap company.

Should I invest in TRACON Pharmaceuticals Inc (TCON)?

Before investing in TRACON Pharmaceuticals Inc (TCON), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.